Nanovibronix, Inc. – Trademark Portfolio
Entity Type: 03
Nanovibronix, Inc. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 14 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include UROSHIELD, PAINSHIELD, WOUNDSHIELD, NANOVIBRONIX, and PAINSHIELD MD PLUS. The owner is based in Cedarhurst, CA.
601 Chestnut Street
Cedarhurst, CA 11516
Showing of trademarks Trademarks
Trademark Classifications
Nanovibronix, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Nanovibronix, Inc. have?
Nanovibronix, Inc. has 20 U.S. trademarks filed with the USPTO. Of these, 5 registered, 7 abandoned, 8 cancelled.
What trademark classes does Nanovibronix, Inc. file in?
Nanovibronix, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 21 (Housewares). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Nanovibronix, Inc.'s most well-known trademarks?
Nanovibronix, Inc.'s registered trademark portfolio includes well-known marks such as UROSHIELD, PAINSHIELD, WOUNDSHIELD, NANOVIBRONIX, and PAINSHIELD MD PLUS. These are among 5 currently registered trademarks in the portfolio.
What is Nanovibronix, Inc.'s trademark registration success rate?
Nanovibronix, Inc. has a 25% trademark registration rate, with 5 out of 20 resolved applications resulting in successful registration. Currently, 0 applications are pending review.